Mainstream

Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs

Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs

Post ContentxeneRead More

You might also be interested in reading Trevi spikes as B. Riley reportedly cites deal prospects.

August 12, 2025
In Mainstream